NanoSyrinx named as winner of the 2022 AbbVie UK Golden Ticket programme

NanoSyrinx has been named as the winner of the 2022 AbbVie UK Golden Ticket accelerator programme.

The 2022 AbbVie UK Golden Ticket is a competitive award, open to early-stage life sciences companies and biotech start-ups that are working to develop cutting-edge therapies or technology platforms. Under the programme, the company will benefit from:

  • One year of free lab space, funded by AbbVie, at Pioneer Group’s BioCity Nottingham site, where NanoSyrinx will have access to core facilities and services

  • Tailored support from AbbVie’s world-leading global and UK scientists, business leaders and mentors

  • Exclusive access to AbbVie and Pioneer Group’s networks over the year with the opportunity for future collaboration

NanoSyrinx CEO, Dr Joe Healey, said:

“We are incredibly proud to have been selected as the winner of the first ever AbbVie UK Golden Ticket. This award recognises the potential of our unique nanosyringe platform to address a wide range of challenges associated with the intracellular delivery of biological therapeutics. We are looking forward to engaging more deeply with the experts from AbbVie and accessing the support of Pioneer Group as we move forward with building our internal pipeline”

The Award was announced today by Belinda Byrne, PhD, AbbVie’s Medical Director in the UK, who said:

“Part of what drives me and excites me about the industry that I work in is the opportunity to make a difference for patients. Supporting discovery science is that very early stage of identifying novel targets of disease, new compounds that may be able to treat a disease, or new ways of getting drugs to exactly where they need to be to treat a particular condition […]

Through the Golden Ticket programme, we have seen some of the fantastic cutting edge science taking place in the UK and are proud to have the opportunity to work with our inaugural winner – NanoSyrinx – to support the development of its novel drug delivery technology.”

For more information, see the announcement here.

Read more news

JPM week 2024: NanoSyrinx highlighted in GEN

NanoSyrinx CEO Joe Healey, and CBO James Lapworth attended the JP Morgan Healthcare conference in San Francisco last week. Among a great week of meetings with collaborators, investors and partners, they sat down with Jonathan Grinstein PhD, a writer for GEN Edge, and spoke about the journey the company had been on and the outlook […]

Read more
Anthony Johnson, NanoSyrinx NED

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Coventry, UK, 10 November 2023: NanoSyrinx, a synthetic biology company developing a novel platform for targeted intracellular delivery of biologic therapeutics, today announced Anthony Johnson, M. D., has joined its Board as Non-Executive Director. Tony’s appointment forms part of the Company’s ongoing strategy to expand and strengthen its leadership team as the Company prepares for […]

Read more

NanoSyrinx to feature in PwC’s Life Sciences Future50 Report

We are delighted to be showcased as one of the 50 companies in PwC UK’s  ‘Life Sciences Future 50’ report, illustrating the world-class science and innovation being led by the UK’s life sciences sector to solve some of the most important challenges in scientific research and human healthcare. Find out more here:

Read more